Optimization of Thermolytic Response to $A_1$ Adenosine Receptor Agonists in Rats

Isaac R. Bailey, Bernard Laughlin, Lucille A. Moore,1 Lori K. Bogren,2 Zeinab Barati, and Kelly L. Drew


Received March 17, 2017; accepted June 22, 2017

ABSTRACT

Cardiac arrest is a leading cause of death in the United States, and, currently, therapeutic hypothermia, now called targeted temperature management (TTM), is the only recent treatment modality proven to increase survival rates and reduce morbidity for this condition. Shivering and subsequent metabolic stress, however, limit application and benefit of TTM. Stimulating central nervous system $A_1$ adenosine receptors ($A_1$AR) inhibits shivering and nonshivering thermogenesis in rats and induces a hibernation-like response in hibernating species. In this study, we investigated the pharmacodynamics of two $A_1$AR agonists in development as antishivering agents. To optimize body temperature ($T_b$) control, we evaluated the influence of every-other-day feeding, dose, drug, and ambient temperature ($T_a$) on the $T_b$-lowering effects of N6-cyclohexyladenosine (CHA) and the partial $A_1$AR agonist capadenoson in rats. The highest dose of CHA (1.0 mg/kg, i.p.) caused ad libitum–fed animals tested to reach our target $T_b$ of 32°C, but responses varied and some rats overcooled to a $T_b$ as low as 21°C at 17.0°C $T_a$. Dietary restriction normalized the response to CHA. The partial agonist capadenoson (1.0 or 2.0 mg/kg, i.p.) produced a more consistent response, but the highest dose decreased $T_b$ by only 1.6°C. To prevent overcooling after CHA, we studied continuous i.v. administration in a manner that resembles spontaneous onset of hibernation in AGS, dietary restriction (DR) in rats sensitizes paralytics suppress shivering and are used commonly with TTM in comatose patients after cardiac arrest (Bernard et al., 2002). With regard to cooling conscious stroke patients, meperidine (i.v.) in combination with buspirone (oral) is currently the treatment of choice to suppress shivering. Synergy between these two drugs decreases shivering threshold to a core body temperature ($T_b$) of 33.5°C with minimal risk of respiratory depression (Mokhtarani et al., 2001; Sessler, 2009; Logan et al., 2011); however, a shivering threshold of 33.5°C is not sufficient for optimal control of shivering at colder $T_b$. The metabolic stress of shivering limits maximum therapeutic benefit of cooling. A recent study (Nielsen et al., 2013) showed no difference in outcome in patients cooled to 33°C versus 36°C and questioned the utility of cooling to 33°C. Importantly, this study reported shivering at 33°C and 36°C, but no differences in adverse effects were seen at these temperatures. Other studies confirm shivering at 36°C (Callaway et al., 2015b). By examining strategies in species that routinely lower $T_b$, such as hibernators, we sought a safer, alternative method of inducing TTM without harmful side effects such as shivering. In Arctic ground squirrels (AGS), stimulation of $A_1$ adenosine receptors centrally (intracerebroventricular) or peripherally (i.p.) using N6-cyclohexyladenosine (CHA) decreases oxygen consumption ($V_O_2$) and leads to a subsequent decrease in $T_b$ in a manner that resembles spontaneous onset of hibernation (Jinka et al., 2011). However, for unknown reasons, the drug is effective only in the hibernation season. Like the hibernation season in AGS, dietary restriction (DR) in rats sensitizes animals to the temperature-lowering effects of CHA when...
compared with their ad libitum (AL)-fed counterparts (Jinka et al., 2010). Although CHA effectively lowers $T_b$ in DR rats, precise control of target temperature has not been achieved in AL rats; and DR is not a viable option for human emergency medicine. Currently, it is not known how dose and environmental temperature influence final body temperature in AL rats when given CHA, an A1-selective full agonist (van der Wenden et al., 1995), or capadenoson, an A1-selective partial agonist (Albrecht-Kupper et al., 2012). The objective of this study was to characterize how dose of CHA, the partial A1 adenosine receptor (A1AR) agonist capadenoson, and environmental temperature influence $T_b$ in freely fed rats for the purpose of precise control of $T_b$ between 32 and 36°C. We measure the rate of oxygen consumption as an indicator of thermogenesis, define individual variability in response to capadenoson and to CHA at a dose higher than tested previously, and show that ambient temperature alone is not sufficient to control the depth of cooling. We report that dynamic control of surface temperature in rats, designed to mimic conductive cooling used clinically, is the most effective means to regulate $T_b$ after CHA.

### Materials and Methods

**Animals.** Experiments were done in accordance with the Guide for the Care and Use of Laboratory Animals, 8th edition (National Research Council, National Academies Press, 2010), and protocols were approved by University of Alaska Fairbanks Institutional Animal Care and Use Committee. Male Sprague–Dawley rats (approximately 90 days old) were obtained from Simonson Laboratories (Gilroy, CA) (experiment B) or from a University of Alaska Fairbanks colony derived from Simonson Laboratories (experiments A and C). All animals were housed in pairs at 21.5–23.0°C on a 12L:12D photoperiod. A summary of experiments and number of animals used can be seen (Table 1).

**Experiment A: DR and AL, 0.5 mg/kg CHA, i.p.** Prior research had shown that DR increases sensitivity to the $T_b$-lowering effects of 0.5 mg/kg CHA, but VO$_2$ was not measured as an indication of thermogenesis. In this study, we asked whether CHA suppresses VO$_2$ prior to the decrease in $T_b$, consistent with suppression of thermogenesis, and test the influence of 36 days of every-other-day feeding on the thermolytic response to CHA.

Temperature data loggers (iButton; Maxim Integrated, Sunnyvale, CA) were coated with wax and surgically implanted into the abdominal cavity and programmed to record temperature every 10 minutes. After a 10– to 14-day postoperative recovery period, rats were either fed every other day (DR) or AL up to 40 days. Feeding or food removal was done at 10–11 AM every day. Body weights were measured every 4 days. Between 36 and 40 days after starting the DR protocol, animals were moved to a clean cage and housed individually at an ambient temperature of 16.2 ± 0.5°C (mean ± S.D.) for 24 hours prior to treatment. Rats were moved to a metabolic chamber for 3 hours prior to treatment with CHA (0.5 mg/kg, i.p.) or vehicle (1.0 ml/kg, i.p.) and remained in the metabolic chamber for 2 hours postinjection. VO$_2$ was measured by open flow respirometry, as detailed below.

**Experiment B: AL Feeding, 1.0 mg/kg CHA, 1.0 and 2.0 mg/kg Capadenoson.** We next investigated the effects of 1.0 mg/kg CHA and 1.0 and 2.0 mg/kg partial A1AR agonist capadenoson in AL-fed rats. Rats were instrumented with iButton data loggers, as described for experiment A. All animals, housed in pairs, were placed at an ambient temperature of 17.0 ± 0.5°C (mean ± S.D.) 24 hours before injections and remained at this ambient temperature until 24 hours after injection. Each of the five pairs of animals received a different treatment per week based on a balanced crossover design (Supplemental Table 1). All treatments were given via i.p. injections and consisted of CHA (1.0 mg/kg), CHA vehicle (1.0 mL/kg), capadenoson (1.0 and 2.0 mg/kg), and capadenoson vehicle (1.0 mL/kg). Heart rate was monitored with a digital stethoscope [Littmann Model 4000 electronic stethoscope (3M, St. Paul, MN)].

**Experiment C: AL Feeding, i.v. CHA at 0.25 mg/kg/h with Surface Temperature Modulation.** Finally, we applied dynamic control of surface temperature to optimize control over $T_b$ with CHA administered by continuous i.v. infusion. A temperature-controlled cage was built to modulate $T_b$ in animals treated with CHA. Two male rats were implanted with telemetry transmitters (CTA-F40; Data Sciences International, New Brighton, MN) inside the abdominal cavity, and ECG leads were secured to the chest wall. The femoral artery was cannulated using 12 cm 3Fr C30PU-RECA1302 polyurethane catheters (Instech, Plymouth Meeting, PA). The femoral vein was also cannulated using C30PU-RJV1420 catheters; both cannula were passed through an interseparacular incision, where they were attached to a two-channel vascular harness (VAD115AB; Instech). For postoperative recovery, animals were housed individually with cotton pads substituted for wood shavings. Sutures were removed 7–10 days after the operation, and catheter maintenance was done by flushing every 5 days using saline, followed by filling with a locking solution of heparin/glycerol (500 IU/mL, 50:50) to prevent clotting. On the day of the experiment, animals were placed on the cage surface with the initial surface temperature set to 17°C. CHA was administered by continuous i.v. infusion (0.25 mg/kg/h). When animals approached a target $T_b$ of 32°C, surface temperature was increased to 32°C to maintain target temperature.

**Drugs.** CHA (CAS 36396-99-3) is eliminated with a half-life of approximately 2 hours when given subcutaneously (Tuovinen and Tarhanen, 2004) and is a full A1AR agonist (van der Wenden et al., 1995). CHA (Sigma-Aldrich, St. Louis, MO) was dissolved in 25% (w/v) hydroxypropyl-$\beta$-cyclodextrin (TCI America, Portland, OR) and then diluted to 2.5% in physiologic saline. CHA vehicle consisted of 25% (w/v) hydroxypropyl-$\beta$-cyclodextrin diluted to 2.5% in physiologic saline. Capadenoson (CAS 544417-40-5) is a partial A1AR agonist relative to 6-chloro-N$^6$-cyclopentyladenosine (CCPA) and shows a half-life of approximately 20 hours (Albrecht-Kupper et al., 2012). Capadenoson (>98% purity; Chemexpess, Monmouth Junction, NJ) was dissolved in 100% polyethylene glycol (PEG400; Med Laboratory Supply, Pompano Beach, FL) and then diluted to 60% polyethylene glycol concentration with sterile water. All substances were USP grade where available. Solutions for injection were sterilized by 0.2 μm filtration (Acrodisc syringe filter; Pall, Port Washington, NY).

**Oxygen Consumption (VO$_2$).** VO$_2$ was measured using open-flow respirometry in conjunction with LabGraph respirometry acquisition and analysis software according to Toien (2013) and Jinka et al. (2011). The accuracy and integrity of the system were calibrated by burning ethanol (100%) following established methodology (Toien, 2013);

### Table 1

<table>
<thead>
<tr>
<th>Experiment</th>
<th>Experimental Test</th>
<th>Drug</th>
<th>Doses</th>
<th>Route</th>
<th>Ambient Temperature</th>
<th>Sample Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Diet and oxygen consumption</td>
<td>CHA</td>
<td>0.5 mg/kg</td>
<td>i.p.-Bolus</td>
<td>16°C</td>
<td>15</td>
</tr>
<tr>
<td>2</td>
<td>↑ Dose of CHA</td>
<td>CHA</td>
<td>1.0 mg/kg</td>
<td>i.p.-Bolus</td>
<td>17°C</td>
<td>10</td>
</tr>
<tr>
<td>3</td>
<td>Compare partial agonist</td>
<td>Capadenoson</td>
<td>1.0 and 2.0 mg/kg</td>
<td>i.p.-Bolus</td>
<td>17°C</td>
<td>10</td>
</tr>
<tr>
<td>4</td>
<td>Surface temperature modulation with i.v. CHA</td>
<td>CHA</td>
<td>0.25 mg/kg/h</td>
<td>i.v.-Continuous</td>
<td>16°C–32°C</td>
<td>2</td>
</tr>
</tbody>
</table>
analyzers were manually calibrated with atmospheric reference air (∼0.03% CO₂), zero air (∼0% CO₂), and span gas (∼0.51% CO₂) before each group of experiments and autocalibrated subsequently every 2 hours. VO₂ data were synchronized with Tb by subtracting a lag time of 4 minutes calculated as the volume of the chamber and length of the outlet tube.

**Statistical Analysis.** Variation in Tb, body mass, and VO₂ was analyzed using repeated-measures linear mixed-effect models (Domínguez, 2004) to account for within-rat correlations and to model time trajectories after treatment or feeding regimen. These statistical analyses were conducted using the IBM SPSS Statistics 19 Armonk, NY. Post hoc comparisons were performed using t tests with Bonferroni corrections (Excel 2007). The significance criterion was α < 0.05 for all analyses. Data are shown as mean ± S.E.M. unless otherwise indicated.

**Results**

**DR; 0.5 mg/kg i.p. CHA.** We investigated the influence of every-other-day feeding on whole animal oxygen consumption and on the circadian rhythm in Tb to assess the influence of DR on thermoregulation. DR decreased Tb compared with animals fed AL [diet × time (F[1,13.10] = 7.95, P = 0.014) and main effect of diet (F[1,12.37] = 8.97, P = 0.011)]. Post hoc tests show that the Tbs in DR animals in comparison with AL were statistically different on days 4–36, except for days 5, 7, and 17 (P > 0.05), as shown in Fig. 1A. Next, we asked whether DR affected Tbs across the circadian rhythm or only during the light or dark phase of the cycle. Analysis of Tbs on the day prior to CHA administration (a feeding day; Fig. 1B) shows that DR decreases the amplitude during the dark, active period [main effect of time (F[1,343] = 5.15, P = 0.024) and diet (F[1,343] = 7.74, P = 0.008)] with a near-significant interaction between diet and time (F[1,343] = 3.48, P = 0.063). Assessment of the rhythm in Tbs during the lights on (inactive) period was confounded by disturbance associated with feeding and cage cleaning. DR also decreased weight gain relative to AL animals [Fig. 1C; diet × time (F[1,13.50] = 6.28, P = 0.026)].

We next assessed the effects of CHA on Tbs or VO₂ in DR- and AL-fed rats. Rats in both DR and AL groups maintained Tbs at approximately 37.5°C when given vehicle (Fig. 2). Both groups responded to 0.5 mg/kg i.p. CHA, but the DR group showed a larger, more consistent response than the AL group (n = 4 AL, n = 4 DR). Within 120 minutes of injection, Tbs in the AL group
reached 35.1 ± 1.2°C, and T_b in the DR group reached 32.5 ± 0.1°C [diet × time × treatment (F[3,140.04] = 18.19, P < 0.001)] with a significant main effect of time \(F[1,140.04] = 59.86, P < 0.001\). Post hoc t tests showed that the CHA group was significantly different from vehicle in DR animals \(P < 0.05\) at 40–120 minutes after injection. The T_b in the AL group after CHA was not different from vehicle \(P > 0.05\). We observed a bimodal distribution in the four AL-fed rats after giving 0.5 mg/kg CHA; two rats maintained T_b similar to vehicle, whereas the other two showed a decrease in T_b similar to DR rats given CHA (Supplemental Fig. 1).

To see whether CHA decreased T_b as a result of an inhibition of thermogenesis, we measured VO_2 as an indirect measure of both shivering and nonshivering thermogenesis in both DR and AL rats. Compared with rats given vehicle, VO_2 tended to decrease in both AL and DR rats within 10 minutes after CHA injection (Fig. 3A). VO_2 stabilized at minimal levels within 30 to 50 minutes after CHA administration and tended to be lowest in the DR group. Pairwise comparisons revealed significant differences between CHA-treated and vehicle-treated DR rats at 40–120 minutes \(P < 0.05\) and also between AL CHA- and vehicle-treated rats between 70 and 120 minutes \(P < 0.05\). The i.p. injections with CHA or vehicle tended to produce an immediate increase in VO_2, except where rats decreased T_b after CHA (Fig. 3B; Supplemental Fig. 2). In these animals, VO_2 decreased before T_b and is consistent with a decrease in thermogenesis.

**AL Feeding:** 1.0 mg/kg i.p. CHA, 1.0 and 2.0 mg/kg Capadenoson, and Vehicles. We tested a higher dose of CHA (1.0 mg/kg) and two doses (1.0 and 2.0 mg/kg) of the partial agonist capadenoson to test the hypothesis that a maximally effective dose or alternative A1AR agonist would decrease variation in both AL and DR rats. The i.p. injections with CHA or vehicle produced a significant decrease in T_b within 10 minutes after CHA injection (Fig. 3; Supplemental Fig. 2). In these animals, the decline in T_b was reduced by the second injection mirrored closely the response to the first injection (Fig. 5); however, in three animals it did not. Statistical analysis on the minimum T_b within 20.5 hours after injection showed that CHA produced a significant decrease in T_b on both injections \(F(2,18) = 36.57, P < 0.001\), with significant differences between CHA first injection and vehicle \(P < 0.001, t\) test) and CHA second injection and vehicle \(P < 0.001, t\) test). Moreover, there was no significant difference between the first and second injection of CHA \(P = 1.000, \text{paired } t\) test). Regression analysis of minimum T_b on the first and second injections yielded an R^2 value of just 0.43 \(P = 0.043\) (Supplemental Fig. 4). Body weight on the day of injection did not predict the magnitude of the cooling response \(P = 0.72, \text{first injection}; P = 0.25, \text{second injection}\). Moreover, neither time nor change in body weight between injections predicted response on the second injection \(P = 0.82\) (Supplemental Table 2). In addition to lowering T_b, CHA caused a 74.5% reduction of heart rate in comparison with vehicle on average within 2 hours of injection.

**Optimization of Thermolytic Response to A1AR agonists**

[Fig. 3](#) shows a significant decrease in VO_2 and a notable decrease in T_b in response to CHA (1.0 mg/kg) in AL animals. Although a dose of 0.5 mg/kg CHA in AL animals resulted in decreases in T_b in two of four animals, the higher dose of CHA (1.0 mg/kg) produced a notable decline in T_b in all animals (10/10). Nonetheless, the magnitude and duration of response still varied between animals (Fig. 4). The lowest minimum T_b recorded was 20.6°C, whereas the highest minimum T_b was 32.5°C. We asked whether this variation was intrinsic to each animal by giving CHA (1.0 mg/kg) to all animals a second time with 1–5 weeks separating the two injections. In 7 of 10 animals, the decline in T_b after the second injection mirrored closely the response to the first injection (Fig. 5); however, in three animals it did not. Statistical analysis on the minimum T_b within 20.5 hours after injection showed that CHA produced a significant decrease in T_b on both injections \(F(2,18) = 36.57, P < 0.001\), with significant differences between CHA first injection and vehicle \(P < 0.001, t\) test) and CHA second injection and vehicle \(P < 0.001, t\) test). Moreover, there was no significant difference between the first and second injection of CHA \(P = 1.000, \text{paired } t\) test). Regression analysis of minimum T_b on the first and second injections yielded an R^2 value of just 0.43 \(P = 0.043\) (Supplemental Fig. 4). Body weight on the day of injection did not predict the magnitude of the cooling response \(P = 0.72, \text{first injection}; P = 0.25, \text{second injection}\). Moreover, neither time nor change in body weight between injections predicted response on the second injection \(P = 0.82\) (Supplemental Table 2). In addition to lowering T_b, CHA caused a 74.5% reduction of heart rate in comparison with vehicle on average within 2 hours of injection.
of a bolus loading dose, animal Tb approached 32°C within continuous i.v. infusion of CHA (0.25 mg/kg/h) in the absence of surface temperature to prevent overcooling. During controlled cage to model surface cooling used clinically and prevented overcooling. We designed and built a temperature-controlled cage to model surface cooling used clinically and adjusted surface temperature to prevent overcooling. During continuous i.v. infusion of CHA (0.25 mg/kg/h) in the absence of a bolus loading dose, animal Tb approached 32°C within 3 hours on a surface temperature of 17°C. Increasing surface temperature to 32°C maintained target temperature and prevented overcooling (Fig. 6). Heart rate declined rapidly at the start of CHA infusion, and bradycardia persisted throughout the infusion (Fig. 6).

Discussion
Thermolytics include antipyretic drugs such as acetaminophen and certain nonsteroidal anti-inflammatory drugs (Sullivan and Farrar, 2011). In this work, we extend the definition of thermolytic to include drugs that suppress thermogenesis and decrease core Tb. Despite the ability of CHA to suppress thermogenesis, precise control of Tb around a predetermined target temperature had yet to be demonstrated prior to this work. Our objectives were to define how dose of CHA and environmental temperature influence Tb in rats treated with CHA. The i.p. bolus injections using CHA at 0.5 and 1.0 mg/kg failed to produce consistent decreases in Tb; however, use of the higher dose decreased Tb in all animals down to or below our target temperature of 32°C at an ambient temperature of 17°C. From this, we hypothesized that overcooling could be prevented with cage surface temperature modulation and thus facilitate management of target Tb. In this work, we report precise control of Tb using CHA coupled with dynamic control of cage surface temperature and show that modulation of dose alone is not sufficient to precisely manage target Tb.

Our results demonstrate robust thermolytic efficacy of CHA in rats and is a refinement of prior attempts with high doses of purine derivatives. AMP was the first purine reported to induce a torpor-like state in rats (Zhang et al., 2006), and both AMP and ATP were later tested in rats to lower Tb for therapeutic benefit (Zhang et al., 2009, 2013). High doses were necessary to promote sufficient cooling, ultimately producing unwanted effects that discouraged further development. AMP induced a hypothermic response in mice (Swoap et al., 2007) and was later found to act as an A1AR agonist (Muzzi et al., 2013); AMP-induced cooling was blocked using an A1AR antagonist in the CNS (Ilfif and Swoap, 2012). Targeting CNS A1AR using CHA to inhibit thermogenesis shows promise as an effective approach to relieve shivering during therapeutic hypothermia (Jinka et al., 2015).

Other nonpurine-based thermolytics currently in development include neurotensin receptor agonists (Choi et al., 2012; Wei et al., 2013), transient receptor potential (TRP) agonists and antagonists (Almeida et al., 2012; Feketa et al., 2014; Feketa and Marrelli, 2015), GABA_A agonists (Cerri et al., 2013), and other unique formulations (Katz et al., 2012a,b, 2015). Using a fixed ambient temperature, several studies demonstrate control of target temperature through modulation of dose and dosing regimens alone to maintain Tb or prevent overcooling (Muzzi et al., 2013; Wei et al., 2013; Feketa et al., 2014); however, thermolytic efficacy of other drugs tested to date in rats has not been as great as CHA.

Few preclinical studies combine dynamic temperature control with thermolytics in search for optimal temperature management protocols (Almeida et al., 2012; Katz et al., 2012b; Cerri et al., 2013). In the clinic, induction methods vary, but may include packing ice into axillary and groin areas and infusing ice-cold i.v. saline. Once target temperature is reached, Tb is usually maintained with water-blanket surface cooling (Luscombe and Andrzejowski, 2006) (Blanketrol or Arctic Sun, etc.) or endovascular cooling. Surface temperature control devices are routinely used in clinical settings and are standard protocol at most hospitals (Callaway et al., 2015a).

Although we found in this study that surface temperature modulation prevented overcooling, our data do not explain the large individual variation in Tb response to CHA. This variation was unexpected because prior work suggested more...
consistent responses between animals (Jinka et al., 2010, 2015). We did not observe significant variation using the same animals with the partial agonist capadenoson, but consistency came at the cost of thermolytic efficacy.

Current knowledge suggests A1AR agonist-induced cooling is due to an inhibition of thermogenesis at a central site of action (Anderson et al., 1994; Tupone et al., 2013). However, peripheral mechanisms such as the inhibition of lipolysis could also impair nonshivering thermogenesis in brown adipose tissue (Asakura, 2004; Viswanadha and Londos, 2006). It is unclear whether these mechanisms are responsible for individual differences in Tb-lowering effects of CHA, but our results reflect what might be expected in a diverse clinical population.

Similar variation in response to CHA is seen in ground squirrels in which sensitivity to CHA depends on the hibernation season. In AGS, stimulation of CNS A1ARs with CHA induces a torpor-like state, but the drug is effective only in the hibernation season (Jinka et al., 2011). Seasonal sensitivity to CHA in AGS precedes a decrease in food intake and is predicted by a gradual decrease in Tb as animals approach the hibernation season. In AGS, stimulation of CNS A1ARs with CHA induces a torpor-like state, but the drug is effective only in the hibernation season (Jinka et al., 2011). Seasonal sensitivity to CHA in AGS precedes a decrease in food intake and is predicted by a gradual decrease in Tb as animals approach the hibernation season (Sheriff et al., 2012; Olson et al., 2013). In rats, prolonged every-other-day feeding increases sensitivity to the temperature-lowering effects of CHA as well as surface expression of A1AR in hypothalamus (Jinka et al., 2010). Although increases in surface expression of A1AR may contribute to increased sensitivity, prolonged restriction of diet is not a viable approach to normalize response to A1AR agonists in emergency medicine.

Shivering is one of the most problematic issues in TTM, which can impede induction of hypothermia by doubling metabolic rate (Badjatia et al., 2008), which leads to a stress-like response. Despite the importance of metabolism reduction, one of the primary desired effects in administering TTM, limited O2 consumption data have been reported for other thermolitics in development. Recently, however, it was revealed that O2 consumption was reduced using TRPv3 agonists to induce hypothermia in mice, but these results could not be replicated in rats (Feketa and Marrelli, 2015). In this work, evidence supporting inhibition of thermogenesis comes from a decrease in the rate of oxygen consumption (VO2) that precedes a decrease in Tb. A similar hysteresis of VO2 and Tb decline is seen during the onset of hibernation and torpor (Jinka et al., 2011).

Generalization of the current results in rats to other nonhibernating species such as swine and humans is likely because rats do not hibernate naturally. By contrast, many strains of laboratory mice spontaneously enter shallow torpor in response to fasting (Geiser, 2004). Results from studies using mice may not translate to species that do not hibernate, as evident in the study of TRPv3 agonists (Feketa and Marrelli, 2015). For this reason, mice are less preferred in the investigation of thermolytic efficacy in comparison with rats or swine.

One limitation of this study and others using small animals to study whole-body cooling is that surface area to weight ratio is far smaller than in larger animals, including humans. An important next step in evaluating thermolytic efficacy is to use larger animals. In the present study, the rate of cooling was faster following i.p. injection than with continuous i.v. administration because a loading dose was not given prior to i.v. infusion. Another limitation not addressed in this work is the potentially detrimental effects of adenosine receptor-induced bradycardia and hypotension, a side effect of CHA and hypothermia (Nieri et al., 2001). We have found previously that coadministration of the peripherally acting adenosine receptor antagonist, 8-sulfophenyltheophylline, reverses bradycardia and improves survival and neurologic outcome after cardiac arrest in rats (Jinka et al., 2015) without interfering with the thermolytic effect of the drug. Work is in progress to characterize the effects of 8-sulfophenyltheophylline on hypotension during CHA-assisted cooling.

A recent trial (Nielsen et al., 2013) showed no difference in outcome in patients cooled to 33°C versus 36°C and questioned the utility of cooling to 33°C. By contrast, an exhaustive number (over 50) of preclinical studies demonstrate that deeper cooling is better (Lyden et al., 2006; Polderman, 2009). Moreover, Nielsen et al. (2013) noted shivering at 33°C and 36°C, and no differences were found in other adverse effects of 33°C versus 36°C; other studies confirm shivering at 36°C (Callaway et al., 2015b). Importantly, the benefit to risk of colder Tb may increase as severity of brain injury increases (Yenari and Han, 2012). In response to the Nielsen et al. (2013) paper, the original International Liaison Committee on Resuscitation recommendations indicating 32–34°C (Dinno et al., 2015) have been changed to recommend a target Tb between 32°C and 36°C (Dinno et al., 2015). The current study is the first report, to our knowledge, of the effects of capadenoson on body temperature. Capadenoson is a partial agonist that produces 75% of full agonist, CCPA, [35S]GTPγS binding in human cortical membranes. In Langendorff heart preparations, capadenoson reduces heart rate to a maximal of 10% of the bradycardia produced by the full agonist CCPA. At higher doses, CCPA produces complete atrioventricular block (Albrecht-Kupper et al., 2012). The limited bradycardia with capadenoson reported by others is consistent with results reported in this study. Given the absence of cardiovascular risk, the mild hypothermic effect of capadenoson may be useful when a target Tb of 36°C is desired.

In summary, we show pronounced thermolytic efficacy of CHA with unexplained variation that is resolved under DR, but is not resolved with dose in AL-fed animals. Although high thermolytic efficacy produced overcooling in some animals, dynamic control of surface temperature allowed for fine tuning and maintenance of a prescribed target Tb. This approach to reduce and maintain target Tb in rodents is a refinement over fixed ambient temperatures or evaporative cooling protocols in which animals are sprayed with water or alcohol to facilitate heat loss (Klahr et al., 2017), and mimics surface cooling used in the clinic. This new thermolytic class of drugs has potential to facilitate targeted temperature management by inhibiting thermogenesis, providing new avenues for treatment.

Acknowledgments
We thank Carl Murphy, Saurav Bhowmick, and Jeanette Moore for technical assistance.

Authorship Contributions
Participated in research design: Drew, Bailey, Laughlin, Moore.
Conducted experiments: Drew, Bailey, Laughlin, Bogren, Moore.
Contributed new reagents or analytic tools: Bailey, Laughlin.
Performed data analysis: Drew, Bailey, Laughlin, Barati.
Wrote or contributed to the writing of the manuscript: Drew, Bailey, Laughlin.
References


